daily californian logo

BERKELEY'S NEWS • OCTOBER 04, 2023

Apply to The Daily Californian by September 8th!

UC Berkeley biochemist Jennifer Doudna talks genome editing, cures to cancer at World Economic Forum

article image

SUPPORT OUR NONPROFIT NEWSROOM

We're an independent student-run newspaper, and need your support to maintain our coverage.

JANUARY 23, 2016

UC Berkeley biochemist Jennifer Doudna joined Vice President Joe Biden this week in a call to advance national research and treatment in the fight against cancer.

During the annual World Economic Forum — which brings together leaders in politics, business and society to shape industry and global agendascancer experts discussed promising tools and methods in the search of cures for cancer. Doudna spoke about her research on CRISPR Cas9, a gene editing tool that can manipulate the human genome.

The meeting, which began Tuesday and concluded Friday, took place in Davos-Klosters, Switzerland. This year’s theme was “Mastering the Fourth Industrial Revolution” and included more than 300 sessions and panels.

Health researchers and scientists presented ways to make cancer treatment and data analysis more accessible, paving the way for future scientific breakthroughs in genetics and nanotechnology as they relate to cancer research. In the United States, cancer is one of the leading causes of death, according to the Centers for Disease Control and Prevention.

Doudna was scheduled to speak at three panels, which were webcasted to the public. Her first panel Tuesday was titled “Cancer Moonshot: A Call to Action.”

Right now, we have the technology to make very precise changes in essentially any type of cell, and including in human embryos,” Doudna said during Thursday’s webcast, “Life in 2030: Humankind and the Machine.” “What’s coming I think, in the future, is the potential to make changes to the human genome that will give us cures for disease.”

During the Thursday panel, Doudna said there are two major challenges that scientists and researchers face with human gene editing: social ethical issues and a general lack of information about the human genome.

Discovering the secrets of the human genome will not only lead to breakthroughs in cancer research, but also affect other scientific endeavours. In response to a panelist’s comment during the meeting, Doudna noted that if humans want to travel in space in the near future, human genome editing is needed as protection against radiation damage and other properties in space that may affect humans.

Among the participants at the forum were Elizabeth Blackburn, former UC Berkeley molecular biologist and 2009 winner of the Nobel Prize for Medicine, and Francis Collins, director of the National Institutes of Health.

“We need a dynamic big-data collection and deploy this as well as we can,” Blackburn said during the forum. As cancer is evolving, we have to promote ways of sharing data among scientists.”

According to Biden in a Jan. 12 blog post, the “moonshot” to find cures for cancer will be aided by the federal government through “funding, target incentives, and increased private-sector coordination.”

Additionally, Biden said in the same post that he will chair meetings with cabinet secretaries and agencies to discuss federal investment and the cancer treatment.

Panelists also made recommendations regarding disease prevention and early cancer-detection methods early at the week-long event. Experts also provided suggestions for faster government approval of drug combinations for treatment.

Doudna’s last panel, “Staying Human,” was Friday evening. The panel focused on maintaining human interests and identities as emerging technologies present new opportunities for enhancing health and advancing productivity.

Contact Robert Tooke at [email protected] and follow him on Twitter at @robertono_t.
LAST UPDATED

JANUARY 24, 2016


Related Articles

featured article
The Intellectual Property and Science division of Thomson Reuters has named UC Berkeley chemistry and molecular and cell biology professor Jennifer Doudna as a citation laureate for her development of the CRISPR-Cas9 genome-editing method.
The Intellectual Property and Science division of Thomson Reuters has named UC Berkeley chemistry and molecular and cell biology professor Jennifer Doudna as a citation laureate for her development of the CRISPR-Cas9 genome-editing method.
featured article
featured article
Disagreement persists between scientists at UC Berkeley and the Massachusetts Institute of Technology over the disputed patent rights to a gene-editing technology known as CRISPR-Cas9 potentially worth billions of dollars.
Disagreement persists between scientists at UC Berkeley and the Massachusetts Institute of Technology over the disputed patent rights to a gene-editing technology known as CRISPR-Cas9 potentially worth billions of dollars.
featured article
featured article
On March 19, researchers led by campus professor of chemistry and molecular and cell biology Jennifer Doudna published an article in an online version of the journal Science advocating open discourse regarding the use of technology that can manipulate the human genome.
On March 19, researchers led by campus professor of chemistry and molecular and cell biology Jennifer Doudna published an article in an online version of the journal Science advocating open discourse regarding the use of technology that can manipulate the human genome.
featured article